Sanofi contest gooses diabetes technological innovation

Share this article:
Social solutions best high tech in Sanofi contest
Social solutions best high tech in Sanofi contest

Sanofi has kicked off its second annual, social-media-driven Data Design Diabetes Innovation Challenge contest, which last year kicked up a wealth of innovative ideas and buzz for the price of $200,000 in prize money and a few salaries.

The prize money “yielded ideas in six months that would have taken four to five years to develop at ten times the cost,” said Sanofi's Dennis Urbaniak, VP US diabetes.

Submissions for the contest, which aims to boost development of apps and other tools to make life easier for people with diabetes, were accepted through March 23. Five semi-finalists will show their work to a panel of judges in May, then two finalists will be awarded $10,000 to participate in a “community uptake exercise.” A winner, to be named in July, gets a $100,000 grand prize. This year Sanofi is adding a “Design and Prototype Bootcamp” for the semifinalists. Participants also get a partnership with Startup America.

Last year's winners, a pair of MIT grads calling themselves Ginger.io, went on to raise $1.7 million in seed funding with their behavior analytics app.

Other pharmas, including Janssen and Novartis, have since launched innovation challenge-style contests, noted Sara Holoubek, CEO of Luminary Labs, the firm Sanofi engaged to work on the contest's design.

“It's a win-win for everyone,” said Holoubek. “Startups are getting media attention and resources. Patients are getting new solutions, and Sanofi is getting new innovations.”
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.